1. Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
- Author
-
Bonaca, Marc, Moslehi, Javid, Ledermann, Jonathan, Michelon, Elisabete, Wei, Caimiao, Moran, Michael, Monk, Bradley, and Pujade-Lauraine, Eric
- Subjects
carcinoma ,clinical trial ,immune checkpoint inhibitors ,immunotherapy ,left ,ovarian epithelial ,phase III ,ventricular function ,Humans ,Female ,Stroke Volume ,Ventricular Function ,Left ,Ovarian Neoplasms ,Doxorubicin ,Carcinoma ,Ovarian Epithelial ,Polyethylene Glycols ,Antineoplastic Combined Chemotherapy Protocols - Abstract
UNLABELLED: In the phase III JAVELIN Ovarian 200 trial, 566 patients with platinum-resistant/refractory ovarian cancer were randomized 1:1:1 to receive avelumab alone, avelumab plus pegylated liposomal doxorubicin (PLD), or PLD alone. Cardiac monitoring was included for all patients. We report left ventricular ejection fraction (LVEF) data from the trial. Grade ≥3 cardiac adverse events (AEs) occurred in 4 (2.1%), 1 (0.5%), and 0 patients in the avelumab, combination, and PLD arms, respectively. LVEF decreases of ≥10% to below institutional lower limit of normal at any time during treatment were observed in 1 (0.8%), 3 (1.9%), and 2 (1.5%) patients, respectively; 4 had subsequent assessments, and these showed transient decreases. No patient had a cardiovascular AE related to LVEF decrease. This analysis is, to our knowledge, the first analysis of LVEF in patients receiving immune checkpoint inhibitors. CLINICALTRIALS.GOV IDENTIFIER: NCT02580058.
- Published
- 2023